Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wonshik Han

Showing results (331-340 of 384) with videos related to

Pageof 39
Sort By:
Cancer Research and Treatment|September 4, 2025
Long-Term Prognostic Value and Analytical Parameters of the Next-Generation Sequencing-Based Multigene Assay in Hormone Receptor-Positive, HER2-Negative Breast CancerHyunji Kim, Jiwon Koh, Hyunwoo Lee, et al.
Cancer Research and Treatment|March 4, 2017
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase InhibitorsKoung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, et al.
Nature Communications|August 29, 2023
Barcoded multiple displacement amplification for high coverage sequencing in spatial genomicsJinhyun Kim, Sungsik Kim, Huiran Yeom, et al.
Clinical Breast Cancer|May 31, 2018
Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer ChemotherapyHee Jeong Kim, Moo Hyun Lee, Jeong Eon Lee, et al.
Journal of Cancer Research and Clinical Oncology|November 19, 2015
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapyHyori Kim, Jeonghwan Youk, Yaewon Yang, et al.
Cancer Letters|February 4, 2006
BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutationsSei Hyun Ahn, Byung Ho Son, Kyung-Sik Yoon, et al.
The Oncologist|June 6, 2023
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast CancerHan-Byoel Lee, Kyung-Hun Lee, Seok Hyun Song, et al.
Scientific Reports|January 15, 2021
S100A8/A9 mediate the reprograming of normal mammary epithelial cells induced by dynamic cell-cell interactions with adjacent breast cancer cellsSeol Hwa Jo, Woo Hang Heo, Hye-Youn Son, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast CancerHan-Byoel Lee, Sae Byul Lee, Minsu Kim, et al.
BMC Cancer|November 3, 2007
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerBhumsuk Keam, Seock-Ah Im, Hee-Jun Kim, et al.
Pageof 39

Showing results (331-340 of 384) with videos related to

Sort By:
Pageof 39
Cancer Research and Treatment|September 4, 2025
Long-Term Prognostic Value and Analytical Parameters of the Next-Generation Sequencing-Based Multigene Assay in Hormone Receptor-Positive, HER2-Negative Breast CancerHyunji Kim, Jiwon Koh, Hyunwoo Lee, et al.
Cancer Research and Treatment|March 4, 2017
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase InhibitorsKoung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, et al.
Nature Communications|August 29, 2023
Barcoded multiple displacement amplification for high coverage sequencing in spatial genomicsJinhyun Kim, Sungsik Kim, Huiran Yeom, et al.
Clinical Breast Cancer|May 31, 2018
Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer ChemotherapyHee Jeong Kim, Moo Hyun Lee, Jeong Eon Lee, et al.
Journal of Cancer Research and Clinical Oncology|November 19, 2015
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapyHyori Kim, Jeonghwan Youk, Yaewon Yang, et al.
Cancer Letters|February 4, 2006
BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutationsSei Hyun Ahn, Byung Ho Son, Kyung-Sik Yoon, et al.
The Oncologist|June 6, 2023
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast CancerHan-Byoel Lee, Kyung-Hun Lee, Seok Hyun Song, et al.
Scientific Reports|January 15, 2021
S100A8/A9 mediate the reprograming of normal mammary epithelial cells induced by dynamic cell-cell interactions with adjacent breast cancer cellsSeol Hwa Jo, Woo Hang Heo, Hye-Youn Son, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast CancerHan-Byoel Lee, Sae Byul Lee, Minsu Kim, et al.
BMC Cancer|November 3, 2007
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerBhumsuk Keam, Seock-Ah Im, Hee-Jun Kim, et al.
Pageof 39